Hepatitis B is a life-threatening and one of the most common liver infections around the globe. It is caused by the hepatitis B virus (HBV), which attacks and injures the liver. HBV can cause both acute and chronic diseases. The risk for chronic infection with hepatitis B varies greatly by age. Approximately 90% of infected infants and up to 50% of infected children age 1–5 years remain chronically infected with HBV. By contrast, approximately 95% of adults recover completely from HBV infection and do not become chronically infected.
CHB infection treated with either interferon or oral antiviral agents. These treatments expected to slow the progression of cirrhosis, reduce the incidence of liver cancer and improve long-term survival. Among antiviral agents entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide (TAF) recommended as the first choice of treatment regimens. Liver transplantation may be considered in cases of chronic liver failure.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market
The Chronic Hepatitis B Virus Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Chronic Hepatitis B Virus market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Chronic Hepatitis B Virus treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Hepatitis B Virus Market Key Facts
-
In 2016, WHO set the target of eliminating chronic HBV as a public health threat by 2030. Elimination of HBV by 2030 will require diagnosis of 90% of people infected with HBV and antiviral treatment of 80% of diagnosed people eligible for therapy.
-
As per DelveInsight’s analysts, the total prevalent cases of CHB were 5,797,240 in 2017, which are expected to rise during the study period (2017-2030).
-
In the United States, in 2017, only 773,850 cases diagnosed with Chronic Hepatitis B.
-
Among the 7MM, the United States accounted for nearly 39% of the total prevalent population of Chronic Hepatitis B in the year 2017.
-
Germany accounted for 564,158 total prevalent cases in 2017, which will probably decrease during the forecast period. In Germany, the diagnosed prevalent cases of CHB were 157,964 in 2017.
Key Benefits of Chronic Hepatitis B Virus Market Report
-
Chronic Hepatitis B Virus market report provides an in-depth analysis of Chronic Hepatitis B Virus Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Chronic Hepatitis B Virus Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Chronic Hepatitis B Virus current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Chronic Hepatitis B Virus market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Chronic Hepatitis B Virus Market
Growth of the Chronic Hepatitis B market is expected to be mainly driven by an increase in prevalent pool owing to rising awareness and WHO initiatives, the anticipated launch of premium price therapies with better functional cure and expected more patients will go for treatment with the help of target set by WHO for 2030 and increasing affordability.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Hepatitis B Virus market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Chronic Hepatitis B Virus market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Chronic Hepatitis B Virus Epidemiology
The epidemiology section covers insights about the historical and current Chronic Hepatitis B Virus patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chronic Hepatitis B Virus Epidemiology Segmentation
-
Total Prevalent Cases of CHB
-
Total Diagnosed Prevalent cases of CHB
-
Age-Specific Cases of CHB
-
Gender-Specific Cases of CHB
-
Treated cases of CHB
-
CHB cases by Impact on Liver (i.e. decompensated and compensated)
Chronic Hepatitis B Virus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Hepatitis B Virus market or expected to get launched in the market during the study period. The analysis covers Chronic Hepatitis B Virus market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Chronic Hepatitis B Virus Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Chronic Hepatitis B Virus market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Chronic Hepatitis B Virus emerging therapies.
The dynamics of the Chronic Hepatitis B market is anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities.
Key Companies operating in the Chronic Hepatitis B Virus market
-
GlaxoSmithKline/ Ionis
-
Janssen Sciences Ireland UC
-
Hoffmann-La Roche
-
Gilead Sciences
-
Assembly Biosciences
-
Vir Biotechnology, Nucorion
-
Pharmaceuticals/Ligand Pharmaceuticals/Medpace
-
Vaccitech Limited
-
Antios Therapeutics
-
Altimmune
-
Hepion Pharmaceuticals
-
Enanta Pharmaceuticals
-
Enyo Pharma
-
Dicerna Pharmaceuticals
And others
Chronic Hepatitis B Virus Therapies covered in the report include:
-
GSK3228836),
-
JNJ-56136379, and JNJ-3989 ± JNJ-6379 + NUC
-
RG7907 + RG7854 + NUC,
-
Selgantolimod (GS-9688)
-
Vebicorvir (ABI-H0731) + NUC
And many more.
At present many potential therapies are being investigated for the management of CHB, and it is safe to predict that the treatment space will experience a significant impact in the coming years owing to the improvement in the rise in the number of healthcare spending across the world.
Table of Content
1. Key Insights
2. Executive Summary
3. Chronic Hepatitis B Virus Competitive Intelligence Analysis
4. Chronic Hepatitis B Virus Market Overview at a Glance
5. Chronic Hepatitis B Virus Disease Background and Overview
6. Chronic Hepatitis B Virus Patient Journey
7. Chronic Hepatitis B Virus Epidemiology and Patient Population
8. Chronic Hepatitis B Virus Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Hepatitis B Virus Unmet Needs
10. Key Endpoints of Chronic Hepatitis B Virus Treatment
11. Chronic Hepatitis B Virus Marketed Products
12. Chronic Hepatitis B Virus Emerging Therapies
13. Chronic Hepatitis B Virus Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Hepatitis B Virus Market Outlook (7 major markets)
16. Chronic Hepatitis B Virus Access and Reimbursement Overview
17. KOL Views on the Chronic Hepatitis B Virus Market.
18. Chronic Hepatitis B Virus Market Drivers
19. Chronic Hepatitis B Virus Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market
Latest Reports By DelveInsight
Chronic Hepatitis B Virus Pipeline Insight
“Chronic Hepatitis B Virus Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Chronic Hepatitis B Virus Market.
Cutaneous Lupus Erythematosus Market
DelveInsight’s “Cutaneous Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cutaneous Lupus Erythematosus market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/